Cere­cor’s $1M Lil­ly deal put it in the right place at the right time to­day

Call it col­lat­er­al — though per­haps tem­po­rary — good for­tune.

When Alk­er­mes $ALKS whis­tled up an in­stant spike for their share price on pos­i­tive Phase III da­ta for their de­pres­sion drug ALK-5461, shares of mi­cro­cap Cere­cor $CERC al­so ig­nit­ed. The stock had bounced up 56% in pre­mar­ket trad­ing be­cause it has a mid-stage drug, CERC-501, that has the same mech­a­nism as the Alk­er­mes can­di­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER